scholarly journals Genetic alterations and functional networks of m6A RNA methylation regulators in pancreatic cancer based on data mining

2021 ◽  
Author(s):  
Juan Zeng ◽  
Heying Zhang ◽  
Yonggang Tan ◽  
Zhe Wang ◽  
Yunwei Li ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Messenger Rna ◽  
Genetic Alterations ◽  
The Cancer Genome Atlas ◽  
Rna Modification ◽  
Functional Networks ◽  
Molecular Alterations ◽  
M6a Rna Methylation ◽  
Molecular Therapeutic ◽  
New Strategies

Abstract Background Pancreatic cancer is a fatal malignancy of the digestive system and the 5-year survival rate remains low. Therefore, new molecular therapeutic targets are required to improve treatments, prognosis, and the survival of patients. N6-methyladenosine (m6A) is the most prevalent reversible methylation in mammalian messenger RNA (mRNA) and has critical roles in the tumorigenesis and metastasis of various malignancies. However, the role of m6A in pancreatic cancer is still unclear. Exploring genetic alterations and functional networks of m6A regulators in pancreatic cancer may provide new strategies for its treatment. Methods In this study, we used data from the Cancer Genome Atlas (TCGA) database and other public databases through cBioPortal, LinkedOmics, UALCAN, GEPIA, STRING, and the database for annotation, visualization, and integrated discovery (DAVID) to systematically analyze the molecular alterations and functions of 20 main m6A regulators in pancreatic cancer. Results We found that m6A regulators had widespread genetic alterations, and that their expression levels were significantly correlated with pancreatic cancer malignancy. Moreover, m6A regulators were associated with the prognosis of pancreatic cancer patients. Conclusions m6A regulators play a crucial part in the occurrence and development of pancreatic cancer. Our study will guide further studies of m6A RNA modification in pancreatic cancer and could potentially provide new strategies for pancreatic cancer treatment.

scholarly journals Genetic alterations and functional networks of m6A RNA methylation regulators in pancreatic cancer based on data mining

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Juan Zeng ◽  
Heying Zhang ◽  
Yonggang Tan ◽  
Zhe Wang ◽  
Yunwei Li ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Messenger Rna ◽  
Genetic Alterations ◽  
The Cancer Genome Atlas ◽  
Rna Modification ◽  
Functional Networks ◽  
Molecular Alterations ◽  
M6a Rna Methylation ◽  
Molecular Therapeutic ◽  
New Strategies

Abstract Background Pancreatic cancer is a fatal malignancy of the digestive system and the 5-year survival rate remains low. Therefore, new molecular therapeutic targets are required to improve treatments, prognosis, and the survival of patients. N6-methyladenosine (m6A) is the most prevalent reversible methylation in mammalian messenger RNA (mRNA) and has critical roles in the tumorigenesis and metastasis of various malignancies. However, the role of m6A in pancreatic cancer is still unclear. Exploring genetic alterations and functional networks of m6A regulators in pancreatic cancer may provide new strategies for its treatment. Methods In this study, we used data from the Cancer Genome Atlas (TCGA) database and other public databases through cBioPortal, LinkedOmics, UALCAN, GEPIA, STRING, and the database for annotation, visualization, and integrated discovery (DAVID) to systematically analyze the molecular alterations and functions of 20 main m6A regulators in pancreatic cancer. Results We found that m6A regulators had widespread genetic alterations, and that their expression levels were significantly correlated with pancreatic cancer malignancy. Moreover, m6A regulators were associated with the prognosis of pancreatic cancer patients. Conclusions m6A regulators play a crucial part in the occurrence and development of pancreatic cancer. Our study will guide further studies of m6A RNA modification in pancreatic cancer and could potentially provide new strategies for pancreatic cancer treatment.

scholarly journals The Role of m6A Ribonucleic Acid Modification in the Occurrence of Atherosclerosis

2021 ◽  
Vol 12 ◽  
Author(s):  
Jie Fu ◽  
Xinghui Cui ◽  
Xiaoyun Zhang ◽  
Min Cheng ◽  
Xiaoxia Li ◽  
...  
Keyword(s):  
Messenger Rna ◽  
Biological Activities ◽  
Rna Modification ◽  
Acid Modification ◽  
Rna Methylation ◽  
Mrna Metabolism ◽  
Modification Process ◽  
M6a Rna Methylation ◽  
The Relationship

The N6-methyladenosine (m6A) modification is the most abundant epitranscriptomic modification in eukaryotic messenger RNA (mRNA). The m6A modification process is jointly regulated by various enzymes and proteins, such as methyltransferases, demethylases and related m6A-binding proteins. The process is dynamic and reversible, and it plays an essential role in mRNA metabolism and various biological activities. Recently, an increasing number of researchers have confirmed that the onset and development of many diseases are closely associated with the molecular biological mechanism of m6A RNA methylation. This study focuses on the relationship between m6A RNA modification and atherosclerosis (AS). It thoroughly summarizes the mechanisms and processes of m6A RNA modification in AS-related cells and the relationships between m6A RNA modification and AS risk factors, and it provides a reference for exploring new targets for the early diagnosis and treatment of AS.

scholarly journals Molecular Characterization and Clinical Relevance of m6A RNA Methylation Regulators in Cervical Cancer

2020 ◽  
Author(s):  
Jin Chen ◽  
Ji He ◽  
Xiaolei Ma ◽  
Xia Guo
Keyword(s):  
Cervical Cancer ◽  
Clinical Relevance ◽  
Cox Regression ◽  
Critical Role ◽  
The Cancer Genome Atlas ◽  
Rna Modification ◽  
Lasso Regression ◽  
Cox Regression Analysis ◽  
Rna Methylation ◽  
M6a Rna Methylation

Abstract Background: RNA modification, such as methylation of N6 adenosine (m6A), plays a critical role in many biological processes. However, the role of m6A RNA modification in cervical cancer (CC) remains largely unknown. Methods: The present study systematically investigated the molecular signatures and clinical relevance of 20 m6A RNA methylation regulators (writers, erasers, readers) in CC. The mRNA expression and clinical significance of m6A-related genes were investigated using data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) cervical cancer cohort. Mutations, copy number variation (CNV), differential expression, gene ontology analysis and the construction of a mRNA-microRNA regulatory network were performed to investigate the underlying mechanisms involved in the abnormal expression of m6A-related genes. Results: We found inclusive genetic information alterations among the m6A regulators and that their transcript expression levels were significantly associated with cancer hallmark-related pathways activity, such as the PI3K-AKT signaling pathway, microRNAs in cancer and the focal adhesion pathway, which were significantly enriched. Moreover, m6A regulators were found to be potentially useful for prognostic stratification and we identified FMR1 and ZC3H13 as potential prognostic risk oncogenes by LASSO regression. The ROC curves of 3, 5 and 10 years were 0.685, 0.726 and 0.741, respectively. The specificity for 3, 5 and 10 years were 0.598, 0.631 and 0.833, the sensitivity were 0.707, 0.752 and 0.811, respectively. Conclusions: Multivariable Cox regression analysis revealed that the risk score is an independent prognostic marker and can be used to predict the clinical and pathological features of CC.

scholarly journals Prognostic Biomarkers in Pancreatic Cancer: Avoiding Errata When Using the TCGA Dataset

Cancers ◽  
2019 ◽  
Vol 11 (1) ◽  
pp. 126 ◽  
Author(s):  
Remy Nicolle ◽  
Jerome Raffenne ◽  
Valerie Paradis ◽  
Anne Couvelard ◽  
Aurelien de Reynies ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Value ◽  
Prognostic Significance ◽  
The Cancer Genome Atlas ◽  
Pancreatic Tumors ◽  
Expression Data ◽  
Web Based ◽  
Molecular Alterations ◽  
Cancer Genome Atlas ◽  
Tcga Dataset

Data from the Cancer Genome Atlas (TCGA) are now easily accessible through web-based platforms with tools to assess the prognostic value of molecular alterations. Pancreatic tumors have heterogeneous biology and aggressiveness ranging from the deadly adenocarcinoma (PDAC) to the better prognosis, neuroendocrine tumors. We assessed the availability of the pancreatic cancer TCGA data (TCGA_PAAD) from several repositories and investigated the nature of each sample and how non-PDAC samples impact prognostic biomarker studies. While the clinical and genomic data (n = 185) were fairly consistent across all repositories, RNAseq profiles varied from 176 to 185. As a result, 35 RNAseq profiles (18.9%) corresponded to a normal, inflamed pancreas or non-PDAC neoplasms. This information was difficult to obtain. By considering gene expression data as continuous values, the expression of the 5312 and 4221 genes were significantly associated with the progression-free and overall survival respectively. Considering the cohort was not curated, only 4 and 14, respectively, had prognostic value in the PDAC-only cohort. Similarly, mutations in key genes or well-described miRNA lost their prognostic significance in the PDAC-only cohort. Therefore, we propose a web-based application to assess biomarkers in the curated TCGA_PAAD dataset. In conclusion, TCGA_PAAD curation is critical to avoid important biological and clinical biases from non-PDAC samples.

scholarly journals Proteogenomic analysis of pancreatic cancer subtypes

PLoS ONE ◽  
2021 ◽  
Vol 16 (9) ◽  
pp. e0257084
Author(s):  
Doris Kafita ◽  
Panji Nkhoma ◽  
Mildred Zulu ◽  
Musalula Sinkala
Keyword(s):  
Pancreatic Cancer ◽  
Notch Pathway ◽  
Public Health Problem ◽  
The Cancer Genome Atlas ◽  
Molecular Processes ◽  
Sequencing Data ◽  
Proteomics Data ◽  
Cancer Subtypes ◽  
Molecular Alterations ◽  
Significant Public Health

Pancreatic cancer remains a significant public health problem with an ever-rising incidence of disease. Cancers of the pancreas are characterised by various molecular aberrations, including changes in the proteomics and genomics landscape of the tumour cells. Therefore, there is a need to identify the proteomic landscape of pancreatic cancer and the specific genomic and molecular alterations associated with disease subtypes. Here, we carry out an integrative bioinformatics analysis of The Cancer Genome Atlas dataset, including proteomics and whole-exome sequencing data collected from pancreatic cancer patients. We apply unsupervised clustering on the proteomics dataset to reveal the two distinct subtypes of pancreatic cancer. Using functional and pathway analysis based on the proteomics data, we demonstrate the different molecular processes and signalling aberrations of the pancreatic cancer subtypes. In addition, we explore the clinical characteristics of these subtypes to show differences in disease outcome. Using datasets of mutations and copy number alterations, we show that various signalling pathways previously associated with pancreatic cancer are altered among both subtypes of pancreatic tumours, including the Wnt pathway, Notch pathway and PI3K-mTOR pathways. Altogether, we reveal the proteogenomic landscape of pancreatic cancer subtypes and the altered molecular processes that can be leveraged to devise more effective treatments.

Bladder cancer genomics

2020 ◽  
Vol 87 (2) ◽  
pp. 49-56
Author(s):  
Salvatore Siracusano ◽  
Riccardo Rizzetto ◽  
Antonio Benito Porcaro
Keyword(s):  
Bladder Cancer ◽  
Cancer Genomics ◽  
Treatment Strategies ◽  
Genetic Alterations ◽  
Point Of View ◽  
The Cancer Genome Atlas ◽  
Molecular Alterations ◽  
Cancer Genome Atlas ◽  
Polymerase Chain ◽  
Muscle Invasive

Until recently, the treatment of bladder cancer, for several years, was limited to surgery and to immunotherapy or chemotherapy. Currently, the extensive analysis of molecular alterations has led to novel treatment approaches. The advent of polymerase chain reaction and genomic hybridization techniques has allowed to investigate alterations involved in bladder cancer at DNA level. By this way, bladder cancers can be classified as papillary or non-papillary based on genetic alterations with activation or mutations in FGFR3 papillary tumors and with inactivation or mutations involving TP53 and RB1 in non-papillary tumors. Recently, the patterns of gene expression allow to differentiate basal and luminal subtypes as reported in breast cancer. In particular, basal cancers are composed of squamous and sarcomatoid pathological findings, while luminal cancers are composed of papillary finding features and genetic mutations (FGFR3). In particular, specific investigative studies demonstrated that luminal cancers are associated with secondary muscle invasive cancer while basal tumors are related to advanced disease since they are often metastatic at diagnosis. Moreover, from therapeutic point of view, different researchers showed that mutations of DNA are related to the sensitivity of bladder cancer while performing cisplatin chemotherapy. In this prospective, the bladder cancer molecular subtyping classification might allow identifying the set of patients who can safely avoid neoadjuvant chemotherapy likely because of the low response to systemic chemotherapy (chemoresistant tumors). In this context, the Cancer Genome Atlas (TCGA) project has improved the knowledge of the molecular targets of invasive urothelial cancers allowing the researchers to propose hypothesis suggesting that agents targeting the genomic alterations may be an effective strategy in managing these cancers, which occur in about 68% of muscle invasive cancers. A future goal will be to combine treatment strategies of invasive bladder cancers according to their genetic mutational load defined by molecular pathology.

scholarly journals PATH-35. RETROSPECTIVE ANALYSIS OF 145 PATIENTS WITH GLIOBLASTOMA; CORRELATING MOLECULAR ALTERATION INCIDENCE WITH DEMOGRAPHICS, TUMOR LOCATION, AND PROGNOSIS

2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi150-vi151
Author(s):  
Mina Lobbous ◽  
ZacK Tucker ◽  
Elizabeth Coffee ◽  
Louis Nabors
Keyword(s):  
Progression Free Survival ◽  
Tumor Location ◽  
Genetic Alterations ◽  
Primary Brain Tumor ◽  
Demographic Variables ◽  
The Cancer Genome Atlas ◽  
Missense Mutations ◽  
Molecular Alteration ◽  
Molecular Alterations ◽  
Cdkn2a Deletion

Abstract Glioblastoma is the most common and most aggressive primary brain tumor in adults. Glioblastoma was the first neoplasm to be systemically studied by The Cancer Genome Atlas and is one of the most molecularly well-characterized tumors in humans. Molecular profiling of glioblastoma is increasingly available and had led to the identifications of multiple prognostic factors as well as potential actionable targets for novel therapies. We identified 145 patients diagnosed with glioblastoma whose tumor tissue was analyzed using next generation sequencing (NGS). The NGS was performed using validated, commercially available panels. We studied somatic genetic alterations with a particular focus on TERT (which was altered in 55.9% of patients in the dataset), CDKN2A (44%), TP53 (39%), EGFR (38.6%), PTEN (31%), IDH1 (20%), and CDK4 (9%). These molecular alterations were analyzed in relation to the patients’ tumor locations, demographics, and outcomes. We used multiple binary logistic regressions to assess whether demographics and tumor location were predictive of the above alterations We also assessed the relationship between molecular alterations and outcomes when controlling for treatment and demographic variables. Among demographic variables, age predicted alterations in IDH1, EGFR, TERT, TP53, and PTEN. Frontal lobe tumors were more likely to be IDH1-mutated, irrespective of patient age. Sex and race did not predict the incidence of the molecular alterations of interest. Analysis of outcomes revealed that, when controlling for treatment and demographic variables, TERT promoter mutations, TP53 nonsense mutations, and EGFR A289V were predictive of a decreased progression-free survival, while CDKN2A deletion, PTEN missense mutations, and EGFR A289V were predictive of decreased overall survival. Our experience highlights the importance of incorporating routine NGS in the management of patients with glioblastoma. More studies are required to evaluate the predictive and/or prognostic values of different molecular alterations.

scholarly journals Proteogenomic Analysis of Pancreatic Cancer Subtypes

2020 ◽  
Author(s):  
Doris Kafita ◽  
Panji Nkhoma ◽  
Mildred Zulu ◽  
Musalula Sinkala
Keyword(s):  
Pancreatic Cancer ◽  
Notch Pathway ◽  
Public Health Problem ◽  
The Cancer Genome Atlas ◽  
Molecular Processes ◽  
Sequencing Data ◽  
Cancer Subtypes ◽  
Molecular Alterations ◽  
Significant Public Health ◽  
Whole Exome Sequencing Data

AbstractPancreatic cancer remains a significant public health problem with an ever-rising incidence of disease. Cancers of the pancreas are characterised by various molecular aberrations, including changes in the proteomics and genomics landscape of the tumour cells. There is a need, therefore, to identify the proteomic landscape of pancreatic cancer and the specific genomic and molecular alterations associated with disease subtypes. Here, we carry out an integrative bioinformatics analysis of The Cancer Genome Atlas dataset that includes proteomics and whole-exome sequencing data collected from pancreatic cancer patients. We apply unsupervised clustering on the proteomics dataset to reveal the two distinct subtypes of pancreatic cancer. Using functional and pathway analysis, we demonstrate the different molecular processes and signalling aberrations of the pancreatic cancer subtypes. We explore the clinical characteristic of these subtypes to show differences in disease outcome. Using datasets of mutations and copy number alterations, we show that various signalling pathways are altered among pancreatic tumours, including the Wnt pathway, Notch pathway and PI3K-mTOR pathways. Altogether, we reveal the proteogenomic landscape of pancreatic cancer subtypes and the altered molecular processes which can be leveraged to devise more effective treatments.

scholarly journals The functions and prognostic values of m6A RNA methylation regulators in thyroid carcinoma

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Zhi-Hao Yu ◽  
Shao-Ting Feng ◽  
Di Zhang ◽  
Xu-Chen Cao ◽  
Yue Yu ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Carcinoma ◽  
Cox Regression ◽  
The Cancer Genome Atlas ◽  
Rna Modification ◽  
Sequencing Data ◽  
Aberrant Expression ◽  
Cox Regression Analysis ◽  
Rna Methylation ◽  
M6a Rna Methylation

Abstract Background N6-Methyladenosine (m6A) is the most common RNA modification and regulates RNA splicing, translation, translocation, and stability. Aberrant expression of m6A has been reported in various types of human cancers. m6A RNA modification is dynamically and reversibly mediated by different regulators, including methyltransferase, demethylases, and m6A binding proteins. However, the role of m6A RNA methylation regulators in thyroid cancer remains unknown. The aim of this study is to investigate the effect of the 13 main m6A RNA modification regulators in thyroid carcinoma. Methods We obtained clinical data and RNA sequencing data of 13 m6A RNA methylation regulators from The Cancer Genome Atlas (TCGA) THCA database. We performed consensus clustering to identify the clinical relevance of m6A RNA methylation regulators in thyroid carcinoma. Then we used LASSO Cox regression analysis to generate a prognostic signature based on m6A RNA modification regulator expression. Kyoto Encyclopedia of Genes and Genomes, Gene Ontology and Gene Set Enrichment Analyses were performed to explore differential cellular processes and signaling pathways between the two groups based on risk signature. Results We found that most of the m6A RNA modification regulators are down-regulated in 450 patients with thyroid carcinoma. We derived a three m6A RNA modification regulator genes-based risk signature (FTO, RBM15 and KIAA1429), that is an independent prognostic biomarker in patients with thyroid carcinoma. Moreover, we found that this risk signature could better predict outcome in male than female. Functional research in vitro demonstrated that the m6A RNA methylation regulators involved in the model acted significant role in the proliferation and migration of thyroid cancer cells. Conclusions Our study revealed the influence of m6A RNA methylation regulators on thyroid carcinoma through biological experiments and three-gene prognostic model.

scholarly journals Genetic characteristics and prognostic implications of m1A regulators in pancreatic cancer

2021 ◽  
Author(s):  
Qingyuan Zheng ◽  
Xiao Yu ◽  
Qiyao Zhang ◽  
Yuting He ◽  
Wenzhi Guo
Keyword(s):  
Pancreatic Cancer ◽  
Cox Regression ◽  
Clinical Stage ◽  
Gene Mutations ◽  
Clinicopathological Characteristics ◽  
The Cancer Genome Atlas ◽  
Rna Modification ◽  
Rank Test ◽  
Single Nucleotide Variants ◽  
Genetic Characteristics

Studies have identified the methylation of N1 adenosine (m1A), an RNA modification, playing an important role in the progression of the tumorigenesis. This study aimed to analyze the genetic characteristics and prognostic value of m1A regulators in pancreatic cancer. In this study, data on gene mutations, single-nucleotide variants (SNVs), and copy number variation (CNV) were obtained from 363 patients with pancreatic cancer in the Cancer Genome Atlas (TCGA) database, and survival analysis was performed using the logarithmic rank test and Cox regression model. The chi-squared test was used to examine the relationship between the changes in m1A regulatory factors and clinicopathological characteristics. And we used ICGC database to verify the reliability of prognostic markers. The results show that changes in m1A-regulating genes are related to clinical stage and that the expression of some m1A-regulating genes is positively correlated with CNV. In addition, the low expression of the “eraser” gene ALKBH1 is related to the poor prognosis of patients with pancreatic cancer, and its expression level has important clinical significance for patients with pancreatic adenocarcinoma (PAAD). Mechanistically, ALKBH1 may participate in the occurrence and development of pancreatic cancer through mTOR and ErbB signaling pathway. The expression of m1A-regulating genes can be used as a prognostic marker for pancreatic cancer. These findings provide valuable clues for us to understand the epigenetics of m1A in pancreatic cancer.

Sign in / Sign up

Export Citation Format

Share Document